TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2172.
Locate Jan Aushadhi KendraClinical Overview
Dihydralazine Hydrochloride Tablets (25mg) is an oral direct-acting peripheral arteriolar vasodilator on the WHO Model List framework. It relaxes arteriolar smooth muscle to reduce systemic vascular resistance and blood pressure. Indicated for moderate-to-severe hypertension and pulmonary arterial hypertension.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 25 mg two to three times daily with meals with water.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Reflex tachycardia, palpitations, headache, flushing, fluid retention. Rare/Severe: Drug-induced lupus erythematosus-like syndrome.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in coronary artery disease and mitral valvular rheumatic heart disease. Monitor for drug-induced lupus with chronic high-dose therapy.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.